The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer by Karpinski, Pawel et al.
Title page
Title:  The  CpG  island  methylator  phenotype  correlates  with  long-range  epigenetic 
silencing in colorectal cancer
Running title: CIMP correlates with LRES in colorectal cancer
Pawel Karpinski  1,  David Ramsey  2,  Zygmunt  Grzebieniak  3,  Maria  M Sasiadek  1* and 
Nikolaus Blin 4*
1 Department of Genetics, Wroclaw Medical University, Poland
2 Department  of  Statistics  and  Mathematics,  University  of  Limerick,  Plassey,  Limerick, 
Ireland 
3 2nd Department of General and Oncological Surgery,Wroclaw Medical University, Poland 
4  Division of Molecular Genetics, Institute  of Human Genetics,  University of Tuebingen, 
Germany
* equal contribution
Corresponding author and reprint requests: 
Prof. Maria Malgorzata Sasiadek
Departament of Genetics; Wroclaw Medical University 
ul. Marcinkowskiego 1;  50-368 Wroclaw, Poland
e-mail: sasiadek@gen.am.wroc.pl
Tel. +48-71-7841256
Fax. +48-71-7840063
Key words: cytosine methylation, methylator phenotype, CIMP, gene silencing, long-range 
epigenetic silencing, LRES.
Grant support:
This study was supported by a grant from the State Committee for Scientific Research, Polish 
Ministry for Scientific Research and Information Technology, no 1423/P01/2007/32, 2007-
2010
Statement of conflict of interests: none to declare 
11
2
Abstract 
The  CpG  island  methylator  phenotype  (CIMP),  characterized  by  an  exceptionally  high 
frequency of methylation of discrete CpG islands, is observed in 18% to 25% of sporadic 
colorectal cancers (CRCs). Another hypermethylation pattern found in CRCs, termed LRES 
(long-range  epigenetic  silencing),  is  associated  with  DNA/histone  methylation  in  three 
distinct gene clusters at chromosome 2q14.2, demonstrating that DNA hypermethylation can 
span larger chromosomal domains and  lead to the silencing of flanking, unmethylated genes. 
We investigated whether these two phenotypes are interrelated in CRCs. The CIMP status of 
148 sporadic CRCs was determined by methylation-specific PCR (MSP). We determined the 
BRAF V600E  mutation  by  mutant  allele-specific  PCR  amplification  (MASA).  The 
methylation status of the  MLH1 gene and of three CpG islands (EN1,  SCTR and  INHBB), 
corresponding  to  three  distinct  clusters  along  2q14.2,  was  determined  by  MS-PCR.  The 
average number of sites showing methylation in CIMP+ tumors was 2.21 compared to 1.22 
for  CIMP-  individuals,  and  this  difference  was  highly  significant (P  = 3.6×10-8,  Mann-
Whitney test). Moreover, all CIMP+ tumors showed hypermethylation of at least one of these 
loci in contrast to CIMP- tumors, where 18 samples (16%) remained unmethylated. The mean 
number of simultaneously hypermethylated CpG islands at  2q14.2 differs significantly for 
CIMP- and CIMP+ tumors suggesting varying effects  of  domain silencing in this  region. 
Given that the number of hypermethylated loci at 2q14.2 likely affects the range of silenced 
flanking genes, high frequency of simultaneous hypermethylation of three CpG islands (EN1, 
SCTR and INHBB) may have potential influence on specific characteristics of CIMP+ CRCs.
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Introduction
Experimental  evidence  accumulated  in  recent  years  indicates  that  transcriptional 
inactivation of tumor suppressor genes within promoter-associated CpG islands by cytosine 
methylation plays an important role in the formation and progression of human cancers (1). 
Hypermethylation specifically localized in promoter regions is often observed in colorectal 
cancer  (CRC)  and  contributes  to  the  silencing  of  a  number  of  genes  including  tumor 
suppressor genes (e.g. CDKN2A, MLH1,  MGMT, APC) (2). In recent years the role of this 
silencing mechanism in the etiology of CRC has been increasingly recognized. Toyota et al.  
originally proposed that a subset of sporadic CRCs display a promoter CpG island methylator 
phenotype (CIMP) which manifests itself as an exceptionally high frequency of methylation 
of discrete CpG islands (3). Although the existence of CIMP has been questioned by some 
investigators, very recent papers have definitively confirmed the presence of a subset of CRCs 
associated with the CpG island methylation of a number of genes across the genome (4, 5, 6).  
Sporadic colorectal tumors displaying CIMP are associated with proximal location, the female 
gender, older age, the BRAF V600E mutation, and the wild-type TP53 genotype. In addition, 
a high degree of microsatellite instability (MSI-H) in CIMP+ tumors is associated with MLH1 
hypermethylation (7, 8).
Long-range epigenetic silencing (LRES), as originally proposed by Frigola  et al., is 
another epigenetic mechanism found to be common in CRCs and contributes to the silencing 
of a number of genes (9). While CIMP+ is defined as methylation at several distinct loci and is 
reflective  of  a  generalized  hypermethylation  within  the  genome,  LRES  is  defined as  the 
silencing  of  long  chromosomal  regions,  leading  to  transcriptional  repression  of  not  only 
hypermethylated but  also unmethylated genes,  lying either  within or on the boundaries of 
silenced domain. This recent finding of Frigola et al. demonstrates that epigenetic silencing is 
not solely a focal event, but concerns a 4Mb domain of chromosome 2q14.2 (9). Frigola et al. 
found that LRES at 2q14.2 was associated with DNA methylation in three enriched CpG 
island clusters (9). It has been discovered that DNA methylation in each of these clusters is 
associated  with  suppression  of  flanking  unmethylated  genes.  Furthermore,  the  level  of 
suppression  of  flanking  unmethylated  genes  was  much  more  pronounced  in  tumors  that 
exhibited a higher number of hypermethylated CpG islands (EN1, SCTR and INHBB), which 
correspond  to  three  enriched  CpG island  clusters  along chromosome  2q14.2.  These  data 
suggest that the extent and spread of DNA hypermethylation may influence the long-range 
suppression  of  neighboring  genes  (9).  Similar  example  of  LRES  was  found  recently  in 
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microsatellite-unstable sporadic CRCs that displayed  MLH1 promoter hypermethylation. A 
silenced region that corresponds to a cluster of genes flanking MLH1 was also associated with 
DNA/histone methylation and concerned 1.1Mb domain of 3p22 (10). 
CIMP  has  been  found  to  be  associated  with  a  significantly  high  frequency  of 
hypermethylation of discrete CpG islands in contrast to LRES, which has an impact on the 
repression of multiple rather than single genes. We hypothesized that CIMP+ tumors may 
display a higher level of CpG island hypermethylation across chromosome band 2q14.2 than 
CIMP-  tumors.  Therefore,  our  study  aimed  at  clarifying  the  issue  of  whether  there  are 
differences between CIMP+ and CIMP- sporadic CRCs with respect to the extent of DNA 
hypermethylation over the 2q14.2.
We found that all the CIMP+ tumors (confirmed by  MLH1 methylation and  BRAF 
mutation), showed hypermethylation of at least one of the loci studied in contrast to CIMP- 
tumors.  More  importantly,  CIMP+  tumors  displayed  an  exceptionally  high  number  of 
methylated sites along 2q14.2 compared to CIMP- tumors.  Our data indicate that in CIMP+ 
tumors the number of hypermethylated CpG islands at 2q14.2 is substantally higher than in 
CIMP- ones. This difference may possibly contribute to a wider range of silenced genes by 
LRES in CIMP+ than in CIMP- tumors.
Results
CIMP
We examined the CIMP status of 148 sporadic colorectal cancer specimens by MSP 
using  a  CIMP specific  marker  panel  (4).  The  overall  results  of  the  CIMP analysis  are 
presented in Table 2. Methylation of CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1 was 
detected  in  39%,  22%,  36%,  30%  and  22%  of  tumors,  respectively.  Figure  1  shows 
representative  results  of  MSP for  nine  genes.  Figure  2  illustrates  the  distribution  of  the 
number of methylated loci from the CIMP-specific marker panel.
Since CIMP was defined as having at least 3 methylated sites out of the 5 studied loci, 
23% (n=34)  of  the  tumors  were  classified  as  CIMP+. A strongly  bimodal  distribution  of 
tumors according to the number of methylated loci was observed (Figure 2). The mean age of 
patients with CIMP+ tumors was higher (67.8 yrs) than of those with CIMP- tumors (63.2 
yrs) (Table 1). There was a significant association between age and CIMP (P = 0.03). There 
was no significant association between CIMP and gender as reported by others (P = 0.7) (4, 5, 
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11).
BRAF V600E mutation, MLH1 methylation in CIMP+ and CIMP- samples.
Recent studies in which the MethyLight technique was used to determine CIMP status 
have  indicated  significant  relationships  between  the  BRAF V600E  mutation,  MLH1 
methylation and CIMP (4, 5). In contrast to MethyLight, MSP is considered a less specific  
and  sensitive  technique.  Therefore,  to  examine  whether  our  CIMP  classification  is 
appropriate, we decided to determine the presence of the BRAF V600E mutation and MLH1 
methylation. As depicted in Table 2, we observed a significant association between both the 
BRAF V600E mutation (P  = 5.1x10-7),   MLH1 methylation  (P  = 1.6x10-5)  and CIMP+ 
tumors.
The DNA methylation status of three CpG islands along the 2q14.2 region in CRCs according  
to CIMP status
In order to study the interaction between CIMP and hypermethylation along 2q14.2, 
we analyzed the methylation status of three CpG islands (associated with  EN1,  SCTR  and 
INHBB genes) representing three clusters of heavily methylated CpG islands in the 2q14.2 
band (9).
We did not find any association between the three CpG islands examined and either 
age  or  sex  (data  not  shown).  The  results  of  the  methylation  status  of  the  CpG  islands 
associated with the EN1, SCTR and INHBB genes are presented in Table 3 and Figure 3. 
Our analysis revealed that hypermethylation of at least one of the CpG islands within 
2q14.2 is a very common event in our CRC samples and was found in 88% (130/148) of 
cases.  The  frequency  of  hypermethylated  genes  varied  from 33% for  EN1  and 30% for 
INHBB to  81%  for  SCTR.  The  methylation  frequency  of  EN1, SCTR  and INHBB  was 
significantly associated with CIMP-positive tumors (P = 3.2 x 10-7; P = 0.002 and P = 0.006; 
respectively). The distribution of the total number of hypermethylated CpG islands differed 
significantly according to CIMP status (P = 1.3 x 10-9 , χ2 goodness of fit test) and the mean 
number of methylated sites was 2.21 among CIMP+ individuals as compared to 1.22 among 
CIMP- individuals (P = 3.6 x 10-8, Mann-Whitney test). In particular, we found that 100% 
(34/34) of the CIMP+ tumors showed hypermethylation of at least one of the studied loci in 
contrast to CIMP- tumors, where 16% (18/114) of the tumors remained unmethylated at each 
of the three examined sites. More importantly, CIMP+ tumors displayed an exceptionally high 
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frequency of concordant hypermethylation of all three CpG islands studied (16/34) (47 %) 
comparing to CIMP- tumors (3/114) (3%). 
Discussion
During  the  past  decade  the  most  widely  studied  epigenetic  abnormality  in  tumor 
development has been the inactivation of tumor suppressor genes by DNA hypermethylation 
in  promoter  regions  (13,  14).  Although what  determines  which  loci  are  affected  remains 
unexplained, it  has become clear that in many tumors some genes show an exceptionally 
increased frequency of DNA methylation. This is particularly apparent in colorectal cancer 
where incidence of hypermethylation of any given gene appears to be much higher than for 
mutations and where a CpG island methylator phenotype was described for the first time (15, 
16). Although the presence of such a phenotype in CRC has been questioned by some groups, 
recent research has clearly confirmed the existence of CIMP (17). This was made possible by 
the use of the newly established marker panel (CACNA1G, IGF2, NEUROG1, RUNX3  and 
SOCS1)  to  classify tumors as either  CIMP+ or CIMP-,  along with additional genetic  and 
epigenetic criteria (4, 6). Apart from a high frequency of methylation of discrete CpG islands, 
tumors displaying CIMP are characterized by a high frequency of the BRAF V600E mutation, 
a high degree of microsatellite instability (MSI-H) associated with MLH1 hypermethylation, 
proximal location, the female gender and older age (4, 7, 8).
We  used  methylation-specific  PCR  (MSP)  to  determine  CIMP  status.  This  is 
considered to be a less precise technique than the recently developed MethyLight Q-PCR (5, 
18).  Therefore,  we  determined  the  presence  of  the  BRAF  V600E  mutation  and  MLH1 
methylation in our cohort, in order to see whether our CIMP classification was appropriate. 
We observed a significant association between the  BRAF mutation,  MLH1 methylation and 
CIMP (P = 5.1x10-7 and 1.6x10-5, respectively).
The frequency of BRAF mutation observed in our CIMP + tumors (~40%) was similar 
to those, observed by  Samowitz  et al.  (~30%) (7). However, other authors reported much 
higher   frequency of  BRAF  mutation among CIMP positives (~70%) (5).  This difference 
probably results from a different criteria of CIMP classification. The precise and coherent 
molecular definition of CIMP is still under investigation, therefore we decided to employ the 
criteria of  Weisenberger  et  al. while  Ogino  et  al.  introduced  their  own  criteria  (4,  5). 
Moreover, the authors can not exclude the population differences in relation of CIMP and 
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BRAF  mutation.  To  authors  knowledge  this  is  the  first  CIMP  study  among  European 
population. 
The observation of  the  strongly  bimodal  distribution of  the  number of  methylated 
tumors in our cohort as well  as relatively high sensitivity (ranging from 73% to 97% for 
SOCS1 and RUNX3, respectively) and specificity (ranging from 77% to 96% for CACNA1G 
and IGF2, respectively) of the markers used is fully consistent with the results of other groups 
(4, 5, 7).
Recent data demonstrate that, apart from DNA methylation, chromatin modifications 
are also involved in aberrant gene silencing in tumorigenesis (9, 10, 19).  One example of 
such epigenetic suppression comes from studies on CRCs and CRC cell lines. Long-range 
epigenetic silencing (LRES), which was recently discovered by Frigola et al., contributes to 
the silencing of a large domain located in chromosome 2q14.2 (9). It was noted   that this 
regional suppression was caused by methylation of histone H3 at Lys9 (H3-K9) independently 
of DNA methylation. However, the level of suppression of flanking unmethylated genes was 
much more pronounced in tumors that exhibited a higher number of hypermethylated CpG 
islands (EN1,  SCTR and  INHBB), which correspond to three enriched CpG island clusters 
found at 2q14.2 (9). 
Given that CIMP probably reflects the global epigenetic status of a cell, we examined 
the mutual relationships between widespread CpG methylation across the genome (by use of 
five marker panel) and LRES by investigating methylation of three markers (EN1, SCTR and 
INHBB) along 2q14.2 band.
 Our  results  show that  there  are  two  significant  differences  between  CIMP+ and 
CIMP-  tumors  in  regard  to  DNA methylation  in  the  2q14.2  band.  All  CIMP+  samples 
displayed  at  least  one  hypermethylated  locus  as  opposed  to  CIMP-  samples,  where  a 
substantial fraction (16%) of tumors were unmethylated at the studied CpG islands.  More 
importantly, almost all the cases of simultaneous hypermethylation of all three CpG islands 
occurred in CIMP+ individuals (P = 1.3×10-9 , Table 3). It is particularly noteworthy that the 
mean number of methylated sites along 2q14.2 was clearly higher for CIMP+ individuals than 
for CIMP- individuals (P = 3.6×10-8). 
Frigola et al. indicated that when simultaneous hypermethylation of these three CpG 
islands  was  displayed  by  a  tumor,  pronounced  suppression  was  also  observed  for 
unmethylated genes located at the boundaries of the 2q14.2 band (9). This observation is of 
particular importance in connection with our results, because there are several genes located 
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at  the  boundaries  of  2q14.2  which  may  play  a  role  in  colorectal  carcinogenesis.  DDX18 
(MrDB), located close to the boundary with 2q14.1, codes for a RNA dependent helicase that 
is activated by c-MYC protooncogene and plays a role in cell growth (20). The GLI2, CLASP1 
and TSN genes are located close to the boundary with 2q14.3. GLI2 is a known oncogene that 
belongs to the sonic hedgehog signaling pathway, which plays a critical role in the regulation 
of the development of cancer and is associated with basal cell carcinoma and breast cancer.  
GLI2 also regulates the expression of the antiapoptotic factor BCL2 (21, 22, 23). CLASP1 has 
a  function  in  mitosis,  preventing  aneuploidy  by  controlling  spindle  and  kinetochore 
functioning (24).  TSP (translin) recognizes single-stranded DNA ends and probably plays a 
role  in  damage recognition (25).  It  should also be noted that  the  EN1  (engrailed 1) gene 
located  in  one  of  the  hypermethylated  domains  within  the  2q14.2  band used by us  as  a 
methylation marker plays a role in the Wnt signalling pathway, which is involved in colorectal  
carcinogenesis (26, 27).
Our data suggest that CIMP+ tumors differ from CIMP- tumors not only with respect 
to CpG methylation, but also with respect to a wider range of suppressed genes within the 
2q14.2 band. This difference may contribute significantly to reducing the expression of genes 
located at the boundaries of the silenced domain. It will be of particular interest to examine 
whether this difference relates only to the 2q14.2 band or whether this phenomenon plays a 
role in regions beyond chromosome 2, as described recently for colorectal, breast, head and 
neck,  bladder,  esophageal  and lung cancer  (10,  28,  29).  Notably,  a  very  recent  paper  by 
Hitchins et al. describes similar LRES where a whole region located in 3p22 spanning 1.1Mb 
was  transcriptionally  suppressed  in  microsatellite-unstable  sporadic  CRCs  that  dispayed 
MLH1 promoter  hypermethylation  (10).  Given  that  MLH1 methylation-associated 
microsatellite instability generally does not occur among sporadic CRCs outside the context 
of CIMP it  can be hypothesized that LRES across 3p22 is specific to CIMP (4, 10). This 
finding together with our results further raise the possibility that CIMP+ tumors tend to be 
more  prone  to  LRES  because  of  tight  connection  of  CpG  islands  and  histone  (H3-K9) 
methylation in mechanism of regional epigenetic silencing.
Nevertheless, the fact that the boundaries of the 2q14.2 band harbor both possible 
tumor  suppressor  genes  and  a  known  oncogene  may  contribute  through  a  significant 
difference in DNA methylation to the specific characteristics of the CpG island methylator 
phenotype and its clinicopathological features.
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Materials and Methods
Patients and samples
Surgically resected frozen tissues of colorectal cancers were obtained from the 2nd 
Department of General and Oncological Surgery, Wroclaw Medical University. The tumors 
analyzed represent  a  cohort  of  148 sporadic  CRC.  Only  patients  with  primary  colorectal 
cancer who had not received preoperative therapy were included. The study was accepted by 
the  Wroclaw  Medical  University  Ethics  Committee.  Genomic  DNA was  prepared  using 
standard phenol-chloroform extraction and ethanol precipitation.
Detection of BRAF V600E mutation 
Mutant  allele-specific  PCR (MASA) was used to  detect  BRAF V600E mutation as 
described previously (30). Briefly, two different forward primers with a single base substituted 
at  the  end  of  the  primer  (5’  –  GTGATTTTGGTCTAGCTACAGT  –  3’  and  5’ 
-GTGATTTTGGTCTAGCTACAGA –  3’)  were  used  to  amplify  the  wild-type  allele  and 
BRAF mutation,  respectively.  The sequence  of  the  common reverse primer used  for  both 
reactions  was  5'  -GGCCAAAAATTTAATCAGTGGA  -  3'.  Both  PCR  reactions  were 
performed separately in 25 μl of reaction volume containing 1x PCR buffer (Qiagen), 1.5 mM 
MgCl2, 200 μM deoxynucleoside triphosphate, 40 ng genomic DNA, 0.2 μM of each primer 
and  0.75U  Taq  DNA Polymerase  (Qiagen).  Both  PCR reactions  were  set  with  an  initial 
denaturation of 2 min at 95°C and subsequent denaturation for 30 s at 94°C, annealing for 30s 
at  64°C,  and extension for  30s  at  72°C in  a  PTC 200 DNA Engine  Thermal  cycler  (MJ 
Research, Inc., Waltham, MA). Thirty-five cycles were used to amplify the PCR product with 
an expected size of 125 base pairs. Because MASA carries the risk of false positive/negative 
results special precautions were taken and all samples were re-examined for the BRAF V600E 
mutation at least two times.
Bisulfite treatment of DNA and Methylation-Specific PCR
Bisulfite treatment of genomic DNA obtained from resected frozen tissues was carried 
out based on the method developed by Herman et al. with minor modifications described by 
Chan et al. (31, 32).
 In  brief,  1  μg of  genomic  DNA was denatured  with 2 M NaOH at  37°C for  10 
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minutes, followed by incubation with 3 M sodium bisulfite (pH 5.0) at 50°C for 16 hours in  
the dark. DNA was then purified using the DNA Isolation Kit (Biological Industries, Israel) as 
recommended by the manufacturer, incubated with 3 M of NaOH at room temperature for 5 
minutes, precipitated with 10 mol/L of ammonium acetate and 100% ethanol, washed with 
70% ethanol, and finally resuspended in 20 μl of distilled water. 
Approximately 50 ng of the modified DNA was used as a template for Methylation-
Specific  PCR  (MSP)  amplifications  with  primers  specific  to  either  the  methylated  or 
unmethylated  promoter  sequences.  The  primer  sequences,  annealing  temperatures  and 
expected  product  sizes  are  listed  in  Table  4. PCR reactions  were  performed in  25  μl  of 
reaction  volume  containing  1x  PCR  buffer  (Qiagen),  1.5  mM  MgCl2,  200  μM 
deoxynucleoside  triphosphate,  0.2  μM  of  each  primer  and  0.75U  Hot-Start  Taq  DNA 
Polymerase (Qiagen). PCR reactions were hot-started at  95°C for 15 minutes, subsequently 
denatured for 30 s at 95°C, with annealing for 30s at the appropriate temperature for each 
primer  and extension  for  30s  at  72°C. Thirty-five  cycles  were  used  to  amplify  the  PCR 
products  to  the  expected  product  sizes  in  a  PTC 200  DNA Engine  Thermal  cycler  (MJ 
Research, Inc., Waltham, MA).
Human  blood  DNA from  a  healthy  subject  methylated  by  SssI  methylase  (New 
England Biolabs) was used as a positive control for the methylated primer set in each PCR 
reaction and untreated bisulfite modified genomic DNA from the same subject was used as a 
positive control for the unmethylated reaction. A water blank was used as a negative control for 
the PCR amplifications. The amplification products were separated on a 2.5% agarose gel and 
visualized by ethidium bromide staining and ultraviolet transillumination.
 CIMP
We characterized the CIMP status of 148 sporadic CRCs by MSP using the panel of 
methylation markers (Table 4) including, CACNA1G (the 1G subunit of the voltage-dependent 
T type calcium channel),  IGF2  (insulin-like growth factor  2),  NEUROG1  (neurogenin 1), 
RUNX3 (runt-related transcription factor 3) and SOCS1 (suppressor of cytokine signaling 1) 
described recently by Weisenberger et al. (4). The use of these 5 markers has been shown to 
have a very high accuracy, specificity and sensitivity for the determination of overall CIMP 
status (4, 6). CIMP+ was defined as the presence of ≥3 methylated CpG islands out of the 
panel of 5, CIMP- as the presence of at most 2 methylated CpG islands (6).
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Methylation along the 2q14.2 
To determine DNA methylation along the 2q14.2 we utilized MSP using the following 
three markers: EN1 (engrailed-1), SCTR (secretin receptor) and INHBB (inhibin beta b). These 
markers correspond to three distinct regions of extensive hypermethylation within 2q14.2 band 
in colorectal  cancers and served altogether  as a  hallmark of hypermethylation at  analysed 
region (9).
Statistical analysis
When using 2 x 2 contingency tables for categorical data,  Fisher’s exact test was used. 
The Mann-Whitney test was used to compare the mean number of methylated sites in CIMP+ 
and CIMP- patients. The Marascuilo procedure for comparing multiple proportions was used 
to correct for the effects of multiple testing. All  P-values are two-sided and  P ≤ 0.05 was 
considered significant.
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Table 1. Age and gender of patients, frequencies, specificity and sensitivity of used markers with respect to CIMP status
 Methylation (%)
Number 
(n)
Mean 
age
(± s.d.)
Female
cases 
(%)
Male
cases 
(%)
CACNA1G 
cases 
(%)
IGF2
cases (%)
NEUROG1 
caces 
(%)
RUNX3 
cases 
(%)
SOCS1 
cases 
(%)
Total 
(148)
64.3
(± 10.6)
63 (43) 85 (57) 58 (39) 33 (22) 53 (36) 45 (30) 33 (22)
CIMP+ 
(34)
67.8
(± 11.3)
P=0.03a
13 (38) 21 (61) 32 (94) 28 (82) 28 (82) 33 (97) 25 (73)
CIMP- 
(114)
63.2
(± 10.2)
50 (44)
P=0.7b
64 (56) 26 (23) 5 (4) 25 (22) 12 (10) 8 (7)
Sensitivity
(%)
— — — 94 82 82 97 73
Specificity
(%)
— — — 77 96 78 89 93
aP  value was calculated by the t-test
bP value was calculated by the Fisher’s exact test
Sensitivity was defined by (n of CIMP+ tumors for a given marker)/ (n of all CIMP+ cases)
Specificity was defined by (n of CIMP- tumors negative for given marker)/(n of all CIMP- cases)
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Table 2. Comparison of CIMP+ and CIMP- tumors with respect to BRAF mutation and MLH1 methylation
      Overall                   CIMP+                 CIMP- Odds ratio for
      CIMP (95%CI)
P value
cases (%) cases (%) cases  (%)
MLH1
yes 15 (10) 11 (32) 4 (3) 13.15 (3.84-44.97) 1.6x10-5
no 133 (90) 23 (68) 110 (97)
BRAF
V600E
mutant 19 (13) 14 (41) 5 (4)
15.26 (4.94-47.09) 5.1x10-7wild-type 129 (87) 20 (59) 109 (96)
P values were calculated by the Fisher’s exact test.
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Table 3. Comparison of CIMP+ and CIMP- tumors with respect to methylation of CpG islands associated with EN1, SCTR and INHBB genes
number (n)
Methylation (%)
EN1
cases (%)
SCTR
cases (%)
INHBB
cases (%)
zero
cases (%)
one
cases (%)
two
cases (%)
three
cases (%)
mean
Total (148) 49 (33) 120 (81) 45 (30) 18 (12) 64 (43) 48 (32) 18 (12) 1.44
CIMP+ 
(34)
24 (70) 34 (100) 17 (50) 0 (0) 8 (23) 10 (29) 15 (47) 1.22
CIMP- 
(114)
25 (22) 86 (75) 28 (24) 18 (16) 56 (49) 38 (33) 3 (3) 2.21
Odds ratio 
for CIMP 
(95% CI)
8.54 (3.61-
20.20)
4.90 (1.85-
13.00)
3.07 (1.38-
6.80)
3.34 
(1.35-
13.95)
0.31 
(0.13-
0.76)
0.83 
(0.36-
1.91)
32.88 (8.69-
124.34)
N.D
P value 3.2x10-7 0.002 0.006 N.D N.D N.D b1.3x10-9 a3.6x10-8
P-values calculated using Fisher’s exact test
a P-value calculated using the Mann-Whitney test
b  P-value calculated using the χ2 goodness of fit test. The null hypothesis is that the distribution of the number of methylated sites does
   not depend on CIMP status
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Table 4. Primer sequences, annealing temperature and product size for MSP analysis
marker methylation
status
forward primer (5’→3’) reverse primer (5’→3’) annealing 
temperature
(°C)
product 
size
(bp)
reference
CACNA1G U TTTTGGAGTTTGTGTTGTTTGGGT CAAATCACCCAAAACCCCAACTA 65 173 (4)
M TTTCGGAGTTCGCGTTGTTCGGGTTT CGAATCGCCCGAAACCCCGACTA 68 173
IGF2 U GTTTATGTTTGTTTGTGTTTTGTTTATTAGT AAACCACCTCCTCAAACAAAACA 55 203 (4)
M CGTTTGTTCGCGTTTTGTTTATTAGC ACCGCCTCCTCGAACGAAACG 65 196
NEUROG
1
U ATTGTTGTGTTGTGTAGGATTGATGG TCACTCAAAAAACCAACCAAACACAT 63 232 (4)
M AGTCGTTAGGGCGTATTTACGTTTTT ATCACTCAAAAAACCGACCGAAC 66 161
RUNX3 U TGGGTTTTATGGTTGTTTGTGTGTTTA CCCTAACAACCACTATTATACATATTCCCATA 63 150 (4)
M GTTTTACGGTCGTTTGCGCGTT CGACCGCTATTATACGTATTCCCGTAA 65 141
SOCS1 U GGATTTTGTTTTTATTGAGTTTTTATTTG ATAAACCATAACATCCAAAAATACACTACA 50 250 (4)
M TTCGCGTGTATTTTTAGGTCGGTC CGACACAACTCCTACAACGACCG 63 163
MLH1 U AGAGTGGATAGTGATTTTTAATGT ACTCTATAAATTACTAAATCTCTTC 53 100 (32)
M GATAGCGATTTTTAACGC TCTATAAATTACTAAATCTCTTCG 53 93
EN1 U AGTTTTGATTATGGGTTTGTT CCCTCAAACACCAATAACAAC 60 129 this study
M TTTGATTACGGGTTCGTC TCGAACACCGATAACGAC 58 129
SCTR U GGGTGTAGTATTTATTGAGTGTGT CCTCAAAAAACATACAAACACC 57 103 this study
M CGTAGTATTTATCGAGTGCGC CGAAAAACGTACGAACACC 60 103
INHBB U TGTTAATGTTTATTTTAATGTGT AACACAAAATACAAAACTCACC 47 129 this study
M TAACGTTTATTTTAACGCGC ACACGAAATACGAAACTCG 55 129
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Figure legends:
Figure 1. Representative methylation-specific PCR for CIMP marker panel, MLH1 gene and 
three  CpG  islands  associated  with  EN1,  SCTR  and  INHBB genes.  PCR  products  were 
amplified  with methylated (M) and unmethylated (U) sequence-specific  primers.  Distilled 
water (H2O) was used as a blank control.  Bisulfite treated DNA from normal lymphocytes 
(NL) and the same DNA methylated by SssI methylase (SssI NL) served as methylated and 
unmethylated  control  sequences,  respectively.  HyperLadder  V  (Bioline)  was  used  as 
molecular weight marker (MW).
Figure 2. Bimodal distribution of the number of methylated loci  in 148 colorectal  tumor 
specimens with numbers of cases presented above the bars.
Figure  3. The  relationship  between  the  CIMP  status  of  CRCs  and  the  simultaneous 
methylation of EN1, SCTR and INHBB genes
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